Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 5

Ezetimibe and simvastatin for the prevention of cardiovascular events in predialysis chronic kidney disease patients: a review

Authors Naderi, Foody J

Received 5 September 2012

Accepted for publication 24 October 2012

Published 20 December 2012 Volume 2012:5 Pages 165—169

DOI https://doi.org/10.2147/IJNRD.S28159

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5


Sahar Naderi,1 JoAnne M Foody2

1Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA

Abstract: The majority of chronic kidney disease patients die of cardiovascular disease prior to reaching end-stage renal disease. The combination of ezetimibe and a statin has been the focus of a number of recent studies, given initial data showing a substantial reduction in low-density lipoprotein with the addition of ezetimibe. However, it is unclear how this low-density lipoprotein reduction impacts cardiovascular disease outcomes. This review will briefly discuss the burden of cardiovascular disease and the pathophysiology of dyslipidemia in chronic kidney disease patients. It will then assess the data regarding the impact of adding ezetimibe to a statin on the general population, and specifically predialysis chronic kidney disease patients.

Keywords: ezetimibe, simvastatin, chronic kidney disease, cardiovascular, prevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]